EEG-based biomarker might help predict psychotic disorders; QuanDx raises money to advance molecular Dx cancer test platform;

> Researchers are studying an EEG-based biomarker that may help predict psychotic disorders in high-risk individuals. Item

> Chembio Diagnostics ($CEMI) has named a veteran executive from companies now part of Siemens' ($SI) and Roche's ($RHHBY) diagnostic divisions as its new CEO. Story

> PerkinElmer ($PKI) will help expand access to in vitro fertilization genetic screening tests made by Good Start Genetics in a new collaboration deal. Release

> California's QuanDx raised a $1.25 million Series B round to help advance development of its molecular diagnostic platform for cancer, plus genetic and infectious diseases. Release

> Madison, WI-based Stemina Biomarker Discovery is raising $10 million to advance biomarker tests for autism. Story

> AdvanDx is seeking 510(k) clearance for a new test for the rapid detection of MRSA from S. aureus-positive blood cultures. Release

Suggested Articles

The ADDF announced its second round of research awards, with a total of $6 million in new funding for diagnostic tests.

Takeda teamed up with Enzyre to develop an at-home diagnostic device that will help people with hemophilia determine their own coagulation status.

Foundation Medicine received a diagnostic approval from the FDA for selecting HR+/HER2- breast cancer patients for treatment with Novartis' Piqray.